Research ExplorerPublicationsDecreased expression of prolyl hydroxylase 1 is associated w...

Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers

Standard

Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers. / Melling, Nathaniel; Grass, Julia; Reeh, Matthias; Tachezy, Michael; Blessmann, Marco; Izbicki, Jakob R; Grupp, Katharina.

In: J CANCER RES CLIN, Vol. 149, No. 10, 08.2023, p. 7579-7585.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Melling, N, Grass, J, Reeh, M, Tachezy, M, Blessmann, M, Izbicki, JR & Grupp, K 2023, 'Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers', J CANCER RES CLIN, vol. 149, no. 10, pp. 7579-7585. https://doi.org/10.1007/s00432-023-04717-y

APA

Melling, N., Grass, J., Reeh, M., Tachezy, M., Blessmann, M., Izbicki, J. R., & Grupp, K. (2023). Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers. J CANCER RES CLIN, 149(10), 7579-7585. https://doi.org/10.1007/s00432-023-04717-y

Vancouver

Melling N, Grass J, Reeh M, Tachezy M, Blessmann M, Izbicki JR et al. Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers. J CANCER RES CLIN. 2023 Aug;149(10):7579-7585. https://doi.org/10.1007/s00432-023-04717-y

Bibtex

@article{0850f967f1cd40f9a0dd9486dea0514a,
title = "Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers",
abstract = "BACKGROUND: Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.AIMS AND SCOPES: This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.MATERIALS AND METHODS: We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.RESULTS: While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.CONCLUSIONS: In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.",
keywords = "Humans, Prolyl Hydroxylases, Prognosis, Colorectal Neoplasms/pathology, Biomarkers, Tumor/metabolism",
author = "Nathaniel Melling and Julia Grass and Matthias Reeh and Michael Tachezy and Marco Blessmann and Izbicki, {Jakob R} and Katharina Grupp",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = aug,
doi = "10.1007/s00432-023-04717-y",
language = "English",
volume = "149",
pages = "7579--7585",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers

AU - Melling, Nathaniel

AU - Grass, Julia

AU - Reeh, Matthias

AU - Tachezy, Michael

AU - Blessmann, Marco

AU - Izbicki, Jakob R

AU - Grupp, Katharina

N1 - © 2023. The Author(s).

PY - 2023/8

Y1 - 2023/8

N2 - BACKGROUND: Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.AIMS AND SCOPES: This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.MATERIALS AND METHODS: We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.RESULTS: While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.CONCLUSIONS: In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.

AB - BACKGROUND: Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.AIMS AND SCOPES: This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.MATERIALS AND METHODS: We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.RESULTS: While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.CONCLUSIONS: In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.

KW - Humans

KW - Prolyl Hydroxylases

KW - Prognosis

KW - Colorectal Neoplasms/pathology

KW - Biomarkers, Tumor/metabolism

U2 - 10.1007/s00432-023-04717-y

DO - 10.1007/s00432-023-04717-y

M3 - SCORING: Journal article

C2 - 36976352

VL - 149

SP - 7579

EP - 7585

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 10

ER -